AR079698A1 - (4 (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(1h-pirrolo-piridin-il)-metanonas y sintesis de las mismas - Google Patents
(4 (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(1h-pirrolo-piridin-il)-metanonas y sintesis de las mismasInfo
- Publication number
- AR079698A1 AR079698A1 ARP100104883A ARP100104883A AR079698A1 AR 079698 A1 AR079698 A1 AR 079698A1 AR P100104883 A ARP100104883 A AR P100104883A AR P100104883 A ARP100104883 A AR P100104883A AR 079698 A1 AR079698 A1 AR 079698A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- alkoxy
- aryl
- alkyl
- ny1y2
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 9
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- -1 carboxy, hydroxy Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 102000001400 Tryptase Human genes 0.000 abstract 1
- 108060005989 Tryptase Proteins 0.000 abstract 1
- 229940122598 Tryptase inhibitor Drugs 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000002750 tryptase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere en la presente memoria a compuestos y composiciones para el tratamiento y la mejora de enfermedades inflamatorias. De manera específica, la presente se refiere a compuestos que tienen una actividad de inhibicion de triptasa y a los intermedios de los mismos, a composiciones farmacéuticas que comprenden tales compuestos, y a un método de tratamiento de sujetos que padecen una afeccion, enfermedad o trastorno que se puede mejorar mediante la administracion de un inhibidor de triptasa que incluye, pero sin limitacion, por ejemplo, asma y otras enfermedades inflamatorias que incluyen la degeneracion macular asociada a la edad. Reivindicacion 1: Un compuesto de formula (1), de forma que Ar es un arilo o un heteroarilo, y el grupo de formula (2) esta en posicion b respecto del grupo de formula (3) en el arilo en el que, la línea doble es un enlace sencillo o un enlace doble; X se elige independientemente del grupo que consiste en N y C-R5; R1 y R2 son cada uno independientemente hidrogeno o alquilo inferior; R3 es arilo, arilalquenilo, cicloalquenilo, cicloalquilo, heteroarilo, heteroarilalquenilo, heterocicloalquenilo, un heterocicloalquilo unido a carbono o alquilo opcionalmente sustituido con uno o más grupos seleccionados de hidroxi, alcoxi, alquiloxicarbonilamino, cicloalquilo, heterocicloalquilo, R6, -OR6, -S(O)mR6 o -C(=O)-R6; R4 es hidrogeno, acilo, alcoxi, alquiloxicarbonilo, carboxi, hidroxi, -C(=O)-NY1Y2 o alquilo opcionalmente sustituido con alcoxi, alquilcarbonilamino, alquilsulfonilamino, hidroxi, -S(O)m-alquilo o -NY1Y2; R5 es hidrogeno, alcoxi, alquiloxicarbonilo, o alquilo opcionalmente sustituido con alcoxi, alquilcarbonilamino, alquilsulfonilamino, hidroxi, -S(O)m-alquilo o -NY1Y2; R6 es arilo o heteroarilo; Y1 e Y2 son independientemente hidrogeno, alquenilo, alquilo, arilo, arilalquilo, cicloalquilo, heteroarilo, heteroarilalquilo o heterocicloalquilo; o el grupo -NY1Y2 puede formar una amina cíclica; y n es 2; o un N-oxido de dicho compuesto, un profármaco de dicho compuesto, una sal farmacéuticamente aceptable de dicho compuesto, un solvato de dicho compuesto o un hidrato de dicho compuesto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28956509P | 2009-12-23 | 2009-12-23 | |
| FR1057606 | 2010-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079698A1 true AR079698A1 (es) | 2012-02-15 |
Family
ID=44246890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104883A AR079698A1 (es) | 2009-12-23 | 2010-12-22 | (4 (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(1h-pirrolo-piridin-il)-metanonas y sintesis de las mismas |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120245199A1 (es) |
| EP (1) | EP2519520A1 (es) |
| JP (1) | JP2013515725A (es) |
| KR (1) | KR20120112600A (es) |
| CN (1) | CN102770431A (es) |
| AR (1) | AR079698A1 (es) |
| AU (1) | AU2010333893A1 (es) |
| CA (1) | CA2785439A1 (es) |
| MX (1) | MX2012007080A (es) |
| RU (1) | RU2012131280A (es) |
| SG (1) | SG181594A1 (es) |
| TW (1) | TW201141861A (es) |
| UY (1) | UY33137A (es) |
| WO (1) | WO2011078984A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| CN105218546B (zh) * | 2015-11-04 | 2017-05-17 | 上海泰坦科技股份有限公司 | 1h‑吡咯并[2,3‑b]吡啶‑3‑羧酸甲酯的合成工艺 |
| TWI757266B (zh) * | 2016-01-29 | 2022-03-11 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| CN114315706A (zh) * | 2021-12-28 | 2022-04-12 | 河北一品生物医药有限公司 | 一种3,4-二氨基吡啶的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4879119A (en) | 1984-02-21 | 1989-11-07 | Yamanouchi Pharmaceutical Co., Ltd. | Patch |
| JP2876058B2 (ja) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | 薬物送達システム |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| EP0431519B1 (en) | 1989-12-04 | 1994-06-15 | G.D. Searle & Co. | System for transdermal albuterol administration |
| WO1992016192A1 (en) | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| JPH07502219A (ja) | 1991-12-18 | 1995-03-09 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 多重層型バリアー構造体 |
| EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| AR033525A1 (es) * | 2000-05-22 | 2003-12-26 | Aventis Pharma Ltd | Arilmetilaminas sustituidas, composiciones farmaceuticas, uso de las mismas para la manufactura de un medicamento |
| GB0012362D0 (en) | 2000-05-22 | 2000-07-12 | Aventis Pharma Ltd | Chemical compounds |
-
2010
- 2010-12-13 EP EP10793404A patent/EP2519520A1/en not_active Withdrawn
- 2010-12-13 CN CN2010800641180A patent/CN102770431A/zh active Pending
- 2010-12-13 SG SG2012042388A patent/SG181594A1/en unknown
- 2010-12-13 RU RU2012131280/04A patent/RU2012131280A/ru unknown
- 2010-12-13 MX MX2012007080A patent/MX2012007080A/es not_active Application Discontinuation
- 2010-12-13 WO PCT/US2010/060006 patent/WO2011078984A1/en not_active Ceased
- 2010-12-13 KR KR1020127018880A patent/KR20120112600A/ko not_active Withdrawn
- 2010-12-13 JP JP2012546019A patent/JP2013515725A/ja not_active Withdrawn
- 2010-12-13 AU AU2010333893A patent/AU2010333893A1/en not_active Abandoned
- 2010-12-13 CA CA2785439A patent/CA2785439A1/en not_active Abandoned
- 2010-12-22 AR ARP100104883A patent/AR079698A1/es unknown
- 2010-12-22 UY UY33137A patent/UY33137A/es not_active Application Discontinuation
- 2010-12-22 TW TW099145124A patent/TW201141861A/zh unknown
-
2012
- 2012-06-05 US US13/488,541 patent/US20120245199A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2012131280A (ru) | 2014-02-10 |
| JP2013515725A (ja) | 2013-05-09 |
| WO2011078984A1 (en) | 2011-06-30 |
| KR20120112600A (ko) | 2012-10-11 |
| MX2012007080A (es) | 2012-07-20 |
| CA2785439A1 (en) | 2011-06-30 |
| AU2010333893A1 (en) | 2012-07-19 |
| EP2519520A1 (en) | 2012-11-07 |
| US20120245199A1 (en) | 2012-09-27 |
| SG181594A1 (en) | 2012-07-30 |
| TW201141861A (en) | 2011-12-01 |
| UY33137A (es) | 2011-07-29 |
| CN102770431A (zh) | 2012-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35146A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| IN2014KN00929A (es) | ||
| MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
| CO6251201A2 (es) | Composiciones y metodos para el tratamiento de3 enfermedades y desordenes oftalmicos | |
| PH12013501557A1 (en) | Glucagon receptor modulator | |
| EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
| MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
| TN2015000391A1 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| EA201001647A1 (ru) | Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов | |
| EA201500182A1 (ru) | 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ | |
| AR094262A1 (es) | Compuestos antivirales para el tratamiento de la hepatitis c | |
| EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
| EA201590284A1 (ru) | Дигидропиридон р1 в качестве ингибиторов фактора xia | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| GEP201706608B (en) | 1 - arylcarbonyl - 4 - oxy – piperidine compounds useful for the treatment of neurodegenerative diseases | |
| MY170922A (en) | Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives | |
| CR20140301A (es) | Derivados de betulina | |
| PH12019500497A1 (en) | Heteroaryl carboxamide compounds as inhibitors of ripk2 | |
| MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
| PH12013500644A1 (en) | Co-crystals and salts of ccr3-inhibitors | |
| PE20121523A1 (es) | Metodo de tratamiento | |
| WO2012172566A3 (en) | Novel sglt inhibitors | |
| AR079698A1 (es) | (4 (4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il)-(1h-pirrolo-piridin-il)-metanonas y sintesis de las mismas | |
| AR086029A1 (es) | Compuesto derivado de fenil-isoxazol, metodo para prepararlo, composiciones y combinaciones que lo comprende, su uso para preparar una composicion farmaceutica para el tratamiento o la prevencion de infecciones virales y metodo para prevenir tales tratamientos o prevenciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |